The National Task Force for Covid-19 of the Indian Council of Medical Research (ICMR) in a bulletin dated March 21, 2020 recommended the use of hydroxychloroquine for
On Friday, the medical journal The Lancet published a large observational study that found hydroxychloroquine showed no benefit against the coronavirus, while
Abstract
Background
Called the second most populated country in the world, India has now been a live study, with the results that proves the benefit of Ivermectin and Hydroxychloroquine
A few initial in vitro studies as well as a proof of concept study by Guatret et al
a Multicentre, parallel-group randomised controlled trial from India
The search strategy described above retrieved a total of 716 published articles
HC+AZ, HC, and placebo groups had 6 (3·9%), 7 (4·6%), and 9 (5·9%) participants go off study medications before completing the medication course (p = 0·716)
"These data convincingly rule out any meaningful mortality benefit," wrote the investigators, who ended the study early and promised to publish the
Free Full Text; Web of Science; A study spanning six continents, led by Dr
Hydroxychloroquine (HCQ) 400 mg is approved by the Drug Controller General of India (DCGI) and recommended by the Research Society for the Study of Diabetes in India (RSSDI) clinical practice recommendations 2017 as add-on therapy after metformin and sulfonylurea in Type 2 Diabetes (T2DM) patients
Searches were performed in PubMed, Web of Science, Embase, Lilacs, the website ClinicalTrials
The study period was only from March to July 2020, and there was a general lack of data from most countries